|
|
Please type responses here: |
|
First Name:
|
|
|
Last Name:
|
|
|
Email Address:
|
|
|
Retype Email Address:
|
|
|
Title:
|
|
|
Institution:
|
|
|
Phone Number:
|
|
|
City:
|
|
|
State/Province:
|
|
|
Postal/Zip Code:
|
|
|
Country:
|
|
|
What topics would you like to see covered in future POC Group Webinars?
|
|
|
Overall, how would you rate your satisfaction with this Point of Care Web Meeting?
|
Extremely satisfied
Very satisfied
Somewhat satisfied
Dissatisfied
|
|
Your feedback helps your webinar producers and sponsors improve the overall quality of their products and services.
|
|
Do you currently use Cepheid tests?
|
Yes
No
|
|
Are you looking to add any new CLIA waived molecular tests this year?
|
Yes
No
|
|
Would you like to be contacted to learn more about Cepheid's POC solutions?
|
Yes
No
|
|
What type of point of care tests do you currently utilize? Please check all that apply:
|
Diabetes monitoring (HbA1c)
Lipid Panel
COVID-19
Flu
Strep
Drugs of Abuse
Other
I do not do point of care testing
|
|
Would you like to know more about Abbott’s HbA1c and cholesterol point of care testing offerings?
|
Yes – Both HbA1c and Cholesterol Testing
Yes- HbA1c only
Yes- Cholesterol only
No
Not Sure
|
|
Are you pleased with your current middleware solution?
|
Yes
No
|
|
Is your organization considering other middleware solutions?
|
Yes
No
|
|
What respiratory testing approach is your facility currently using for COVID-19 and influenza?
|
Separate rapid antigen tests for COVID-19 and influenza
Combination COVID-19/Flu rapid antigen test
Molecular COVID-19/Flu test
Combination of rapid antigen and molecular testing
We do not currently perform respiratory testing onsite
Not sure / Other
|
|
Following today’s discussion of the COVID-19 EUA transition, how interested would your facility be in evaluating an FDA-cleared COVID-19/Flu rapid test?
|
Very interested — we are actively evaluating alternatives
Interested — we would like additional information
Possibly interested — depending on our facility’s needs
Not currently considering a change
Not applicable / already using an FDA-cleared option
|
|
Would you like to receive ASCLS PACE credit for this session, program number 174-019-26? (If no, you do not need to complete the following questions.)
|
Yes
No
|
|
To receive ASCLS PACE credit (PACE Program number 174-019-26, California Agency #0001) for "From Lab to Front Line: POCT at the Tip of the Spear in Crisis Response" presented on October 7, 2026, you will be required to complete the following program evaluation.
|
|
If the following is true, please answer "Yes": I have attended the full instructional time for this program. I understand that completion of the program is necessary to receive the contact hours awarded for the program.
|
Yes
No
|
|
SPEAKER RATING
|
|
To what extent was the speaker knowledgeable, organized and effective during the presentation? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
To what extent did the speaker clarify and focus on the stated objectives? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
To what extent were the speaker's teaching methods & aids appropriate & effective? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
OBJECTIVES RATING:
To what extent was each objective achieved?
|
|
Define point-of-care testing (POCT) and describe the evolution of its role in crisis response. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Identify challenges encountered during POCT implementation in crisis response settings and discuss potential solutions. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Describe potential applications of artificial intelligence (AI) to support POCT during crisis response. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Discuss strategies to overcome POCT connectivity challenges in communication-limited or communication-denied environments. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
PROGRAM CONTENT RATING
|
|
To what extent did the program content relate to the program's objectives? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Rate the contribution of this session to your overall knowledge of this subject. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Rate your overall degree of satisfaction with this session. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Comments:
|
|
|
Thank you for attending this PACE approved program and completing this evaluation. Questions? Call Whitehat Communications at 434 202 8365.
|
|
By submitting this evaluation, Whitehat uses your information to communicate with you regarding this webinar and other educational events.
https://www.whitehatcom.com/privacy_policy.htm
|
|
|
